Genelux · pitchdeck
Genelux | Investor Presentation Deck | 37 slides
37 pages · 0 arc beats · 0 loops
Genelux | Investor Presentation Deck | 37 slides
Genelux · 2024-02 arc beats above · slides in the middle · loops below · scroll → 0 LOOPS
12468101214161820222426283032343637
Deck intelligence map
1 coverage by narrative range · generated from this deck JSON
Narrative range 37 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Whole deck 37 slides 100% 37/37 slides 100% 37/37 slides · 201 hits — 0/37 slides
62.2% 23/37 slides · 24 hits 29.7% 11/37 slides — 0/37 slides
— 0/37 slides
Slide inventory
37 every slide · same image gating as the playbook
04
The slide uses a three-column layout to summarize key value propositions supported by clinical trial data.show_traction
05
The slide uses a Gantt-style visualization to show clinical trial progress across different indications and routes of administration.plan_implementation
06
Uses a process flow diagram to illustrate the transition from cold to hot tumor states.present_solution
07
The central diagram illustrates the biological mechanism of action, contrasting 'Absence of Effector T Cells' (Platinum resistant) with 'Presence of Effector T present_solution
08
Uses a pyramid/staircase diagram to show progression of clinical advantages.argue_timing
09
The slide uses a document-style callout for key takeaways and a vertical list of icons for clinical results.summarize
10
The slide outlines the trial parameters (n=27) and highlights the transition to the OnPrime Phase 3 trial.show_traction
11
Data presented in a table format comparing patient cohorts against clinical metrics.show_traction
12
Waterfall plot and spider plot showing patient-level clinical outcomes.show_traction
13
The slide uses a before-after comparison for three specific patients (15B-01, 15B-15, 15B-17) to demonstrate clinical efficacy.show_traction
14
Includes a comparison table of historical data vs ELAHARE and a specific VIRO-15 clinical outcome table.show_traction
15
The slide uses a bar chart to compare efficacy metrics (RECIST1.1, CA-125, PFS-6-month) across various clinical studies, with Genelux's VIRO-15 trial highlightesummarize
16
The slide outlines a clinical trial protocol, specifically a randomized open-label study comparing an experimental arm to an active comparator arm.present_framework
17
Includes Kaplan-Meier survival curves and patient cohort descriptions for two separate study groups.show_traction
18
Includes specific patient case reports with RECIST criteria and biomarker data.show_traction
21
The slide highlights the synergy between two existing therapies (TVI and Olvi-Vec) to create a new modality.present_solution
22
The slide uses a hub-and-spoke style layout to categorize strategic pillars.plan_implementation
23
The slide uses a combination of a bulleted list and a hub-and-spoke style visual representation of facility locations.summarize
24
The slide categorizes the platform's capabilities into therapeutic genes, immune modularity, and therapeutic antibodies.present_solution
25
The slide highlights key competitive moats including patent counts, freedom to operate, and regulatory protections.present_solution
27
Includes specific footnotes regarding market close date, cash reporting date, and PIPE commitment details.analyze_data
28
The slide uses a dual-track visual: a list for past milestones and two curved arrows for future milestones.plan_implementation
31
The slide lists key clinical advisors, highlighting their leadership roles in major oncology organizations and clinical trials.other
32
The slide uses two distinct chart types (spaghetti plot and waterfall plot) to validate the efficacy of the treatment.show_traction
33
Includes a patient profile, a bar chart comparing PFS across treatment lines, and a longitudinal line chart tracking tumor size and CA-125 levels.show_traction
34
Includes patient-specific histological evidence (Pt.#15A-01 and Pt.#15A-11) demonstrating the mechanism of action.show_traction
35
The slide uses histology images and HALO infiltration histograms to demonstrate the mechanism of action and clinical efficacy.show_traction
36
The slide uses a combination of clinical timeline, patient history, and immunological data (ELISPOT) to correlate T-cell response with clinical outcome.show_traction
37
The slide uses clinical study data (VIRO-15, NCT01443260) to validate the mechanism of action.present_solution